MYK-224

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cardiomyopathy, Hypertrophic

Conditions

Cardiomyopathy, Hypertrophic

Trial Timeline

Jan 18, 2023 → Feb 27, 2025

NCT ID

NCT05556343

About MYK-224

MYK-224 is a phase 2 stage product being developed by Bristol Myers Squibb for Cardiomyopathy, Hypertrophic. The current trial status is terminated. This product is registered under clinical trial identifier NCT05556343. Target conditions include Cardiomyopathy, Hypertrophic.

What happened to similar drugs?

7 of 20 similar drugs in Cardiomyopathy, Hypertrophic were approved

Approved (7) Terminated (1) Active (12)

✅Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosinAstraZenecaApproved

✅RanolazineGilead SciencesApproved

✅Ranexa + PlaceboGilead SciencesApproved

✅TafamidisPfizerApproved

✅MavacamtenBristol Myers SquibbApproved

✅AcoramidisBayerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05556343	Phase 2	Terminated	Jan 18, 2023	Feb 27, 2025	Cardiomyopathy, Hypertrophic
NCT05686096	Phase 1	Completed	Jan 16, 2023	Apr 8, 2023	Healthy Volunteers
NCT05405543	Phase 1	Completed	Jul 12, 2022	Dec 9, 2022	Healthy Volunteers

Competing Products

20 competing products in Cardiomyopathy, Hypertrophic

See all competitors

Product	Company	Stage	Hype Score
Tideglusib + Placebo	AMO Pharma	Phase 2	32
Mavacamten	LianBio	Phase 1	19
Mavacamten + Placebo	LianBio	Phase 3	30
CT-G20 + Placebo	Celltrion	Phase 1	21
Eplontersen + Placebo	AstraZeneca	Phase 3	44
Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosin	AstraZeneca	Approved	43
AZD0233 + AZD0233 Placebo	AstraZeneca	Phase 1	21
AZD4063	AstraZeneca	Phase 1	36
Eplontersen	AstraZeneca	Phase 3	47
Eplontersen + Placebo	AstraZeneca	Phase 3	44
candesartan	AstraZeneca	Phase 2	31
LCZ696 + Placebo	Novartis	Phase 2	35
Darbepoetin alfa	Amgen	Pre-clinical	26
Eleclazine + Placebo	Gilead Sciences	Phase 2/3	30
Ranolazine	Gilead Sciences	Approved	43
Ranexa + Placebo	Gilead Sciences	Approved	43
Ranolazine	Gilead Sciences	Pre-clinical	18
NNC6019-0001 + Placebo (NNC6019-0001)	Novo Nordisk	Phase 3	47
NNC6019-0001	Novo Nordisk	Phase 2	39
NNC6019-0001 + Placebo (NNC6019-0001)	Novo Nordisk	Phase 2	35